Heads Cross Border Mergers & Acquisitions, Banking & Finance Department
Dr. Ziv Preis is co-head of the firm's Cross Border Mergers & Acquisitions, Banking & Finance Department. His practice focuses on domestic and international mergers and acquisition and corporate finance, including private equity and investment funds, fund formation, cross border mergers and acquisitions, joint ventures, corporate governance, commercial and technology.
Mr. Preis has advised public and private companies, funds, institutional investors and entrepreneurs. Ziv counts among his clients, during his work experience in Israel and the United States, Tnuva Group, Azrieli Group, Casa Cuervo, Starwood Capital, Tyco, Pitney Bowes, Altshuler Saham and Tel Aviv University. Ziv advised on a wide variety of industries, including food and beverage, financial institutions, telecommunication, real estate, gaming, consumer products, medical devices and technology.
Ziv is recognized by Chambers and Partners and Legal500 in the fields of Corporate and Mergers & Acquisitions. “Sources are highly impressed by Ziv Preis … He is lauded for his in-depth understanding of complex M&A transactions, and his ability to resolve complex matters in an efficient and innovative manner“ (Chambers and Partners). “… ‘a deal-making approach’ … Ziv Preis is ‘smart, tireless and pleasant to work with’“ (Legal500).
Ziv was the founding partner of Preis, Baharav & co.; a corporate partner at Herzog, Fox & Neeman; and, prior to that, a senior corporate attorney at the Mergers & Acquisitions department of White & Case, in New York.
Ziv was a recipient of numerous prizes and scholarships, including the John M. Olin Prize for best paper in law and economics at Harvard Law School in 2002, the Irving Oberman Memorial Award for best paper in technology law at Harvard Law School in 2002, the John M. Olin Fellowship, the Academic Excellence Scholarships at Tel Aviv Law School and the Academic Scholarship of Honor Student Program at Tel Aviv University School of Economics. Ziv also lectured at Tel-Aviv University Law School on Mergers and Acquisitions, Tel Aviv University Business School on Business Law, and at Harvard College on the interaction of antitrust laws and intellectual property.
Ziv is admitted to practice law in Israel and New York.
Harvard Law School (Doctor of Juridical Science)
Tel Aviv University (LL.B., Valedictorian; First in Class)
Tel Aviv University School of Economics (B.A. and M.A)
Israel Bar Association, 2001
New York Bar, 2003
News & Publications
A Black Swan in M&A COVID 19 Lake: A Material Adverse Effect that Could Strike at Merger and Acquisition Deals
Many mergers and acquisitions, including investments, have a time period between signing the transaction agreement and closing the transaction. Several factors may lead to that time period such as the need to obtain regulatory approvals (e.g., Competition Authority, the Israeli Lands Authority) to complete the transaction or to obtain the approval of the target company’s […]
You Exercised Your 102 Options to Shares As An Employee – You’re Not Necessarily a Shareholder
An employee exercising options to company’s shares is not necessarily a shareholder with shareholders rights as long as those shares are held by the trustee According to a recent decision in the Haifa District Court – Civil Case 19042-03-18 Navon vs. Sol Chip Ltd. – an employee has been granted options to purchase shares of […]
Water Technology in Brazil
The relationship between Brazil and Israel, in the techno-cultural arena, is heating up. Dr. Ziv Preis, Heads Cross Border Mergers & Acquisitions, Banking & Finance Department, on the challenges and opportunities for water and agriculture on page 10. to read more please click here
Israeli Medical Cannabis Export
Yesterday, the Israeli cabinet approved the long-awaited export of medical cannabis from Israel. The Israeli cabinet decided to permit export of medical cannabis products to countries that accepted the Single Convention on Narcotic Drugs of 1961 and willing to import medical cannabis from Israel. Export of medical cannabis products will be permitted, but no plants, […]